Protalix eyes Fabry drug resubmission thanks to multiple phase 3 readouts
Protalix eyes Fabry drug resubmission thanks to multiple phase 3 [...]
Onconova takes early steps on long road back, filing to raise dose cap in solid tumor trial
Onconova takes early steps on long road back, filing to [...]
After megaround, Apexigen inks modest SPAC deal to advance melanoma prospect toward approval
After megaround, Apexigen inks modest SPAC deal to advance melanoma [...]
Zosano’s headaches continue: Biotech lays off 31% after FDA rejects migraine drug resubmission
Zosano’s headaches continue: Biotech lays off 31% after FDA rejects [...]
Chutes & Ladders—Former Translate CMO Ann Barbier is moving to Camp4 Therapeutics in the same role
Chutes & Ladders—Former Translate CMO Ann Barbier is moving to [...]
NIH squashes Synairgen’s COVID therapy from ACTIV-2 trial after omicron shakes up study
NIH squashes Synairgen’s COVID therapy from ACTIV-2 trial after omicron [...]
Athenex cuts jobs, narrows focus to cell therapies in continued fallout from 2021 FDA rejection
Athenex cuts jobs, narrows focus to cell therapies in continued [...]
Sensorion spins hearing loss flop into exploratory win in attempt to revive lead program
Sensorion spins hearing loss flop into exploratory win in attempt [...]
Bridging the preclinical to clinical divide: practical considerations for biomarker success
Bridging the preclinical to clinical divide: practical considerations for biomarker [...]
Shionogi’s COVID-19 antiviral heads to phase 3 backed by NIH after receiving FDA go-ahead
Shionogi’s COVID-19 antiviral heads to phase 3 backed by NIH [...]